随着低密度脂蛋白胆固醇（LDL-C）与动脉粥样硬化性心血管疾病（ASCVD）的关联性被充分研究，LDL-C的调控目标正朝着越来越低的方向发展，意味着患者需要接受降脂药物强化治疗。他汀类药物作为降低LDL-C的一线药物，疗效与不良反应存在明显个体差异，有少数患者接受他汀类药物治疗时更容易发生严重不良反应。通过搜索众多数据库中与他汀遗传标记物相关的研究，分析他汀类药物疗效及不良反应相关的遗传标记物，为个性化应用他汀类药物提供参考和建议。

As the association between low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD) is well studied, the regulatory goals of LDL-C are moving in a lower and lower direction, implying that patients need to receive intensive treatment of lipid-lowering drugs. As a first-line drug for lowering LDL-C, statins have obvious individual differences in efficacy and adverse reactions, and a small number of patients are more likely to have serious adverse reactions when treated with statins. In this paper, a number of databases related to statin genetic markers are searched to analyze the efficacy of statins and genetic markers associated with adverse reactions, and provide references and recommendations for the personalized application of statins.